NasdaqGS - Nasdaq Real Time Price USD

Crinetics Pharmaceuticals, Inc. (CRNX)

50.44 +1.06 (+2.15%)
As of 11:58 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. R. Scott Struthers Ph.D. Founder, President, CEO & Director 978.34k 5.65M 1963
Dr. Stephen F. Betz Ph.D. Founder & Chief Scientific Officer 672.66k -- 1966
Mr. Marc J. C. Wilson Chief Financial Officer 642.25k 408.5k 1979
Mr. Jeff E. Knight Chief Operating Officer 657.31k -- 1971
Dr. Alan S. Krasner M.D. Chief Endocrinologist 653.92k 125.93k 1963
Mr. James Hassard Chief Commercial Officer 623.5k -- 1966
Ms. Garlan Adams General Counsel & Corporate Secretary -- -- --
Ms. Adriana Cabre M.B.A. Chief Human Resources Officer -- -- --
Mr. Kevin Capps Head of Intellectual Property -- -- --
Mr. Chris Robillard M.B.A. Chief Business Officer -- -- --

Crinetics Pharmaceuticals, Inc.

6055 Lusk Boulevard
San Diego, CA 92121
United States
858 450 6464 https://www.crinetics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
290

Description

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Corporate Governance

Crinetics Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 7. The pillar scores are Audit: 4; Board: 7; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Aug 06, 2024 - Aug 12, 2024
Crinetics Pharmaceuticals, Inc. Earnings Call

Related Tickers

MRUS Merus N.V.
45.57
+1.78%
 
CYTK Cytokinetics, Incorporated
59.94
+0.98%
 
JANX Janux Therapeutics, Inc.
48.55
+1.34%
 
DNLI Denali Therapeutics Inc.
20.45
+3.54%
 
APGE Apogee Therapeutics, Inc.
53.36
-1.19%
 
SNDX Syndax Pharmaceuticals, Inc.
21.98
+1.48%
 
BHVN Biohaven Ltd.
38.31
+2.88%
 
ASND Ascendis Pharma A/S
126.16
+1.07%
 
ARGX argenx SE
375.05
+5.35%
 
TARS Tarsus Pharmaceuticals, Inc.
39.10
+2.92%